FGF19 and hepatocellular carcinoma: However, unlike, for instance, FGFR1 in non‐small‐cell lung cancer (NSCLC) and squamous cell lung cancer (Weiss et al., 2010) or FGF19 in hepatocellular carcinoma (HCC) (Sawey et al., 2011), recurrent gene amplification of FGFs or FGFRs was not detected in MPM and thus cannot account for the frequent overexpression of several FGF/R family members found in MPM (Marek et al., 2014).